Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enanta Pharmaceutica (NQ: ENTA ) 12.70 +0.21 (+1.68%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enanta Pharmaceutica < Previous 1 2 3 4 5 6 7 Next > Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET August 08, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer August 08, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals August 01, 2022 Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Via Benzinga Analyst Ratings for Enanta Pharmaceuticals July 01, 2022 Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings: Via Benzinga Expert Ratings for Enanta Pharmaceuticals June 01, 2022 Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Via Benzinga Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022 August 01, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Recap Of Friday's Biotech Catalysts - End of The Day Summary July 29, 2022 Via Benzinga Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study July 29, 2022 Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple... Via Benzinga Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update July 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants July 29, 2022 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a... Via Benzinga Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19 July 29, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? July 07, 2022 Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? Via Investor's Business Daily This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B June 28, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 July 06, 2022 Upgrades Via Benzinga Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid June 22, 2022 Another company says it invented the technology behind the pill first. Via Investor's Business Daily The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral June 22, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer June 21, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 June 08, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Participate in Two Investor Conferences in June June 02, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 June 01, 2022 Upgrades Via Benzinga The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate May 19, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint May 18, 2022 Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial... Via Benzinga Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) May 18, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire 10 Biggest Price Target Changes For Tuesday May 10, 2022 Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. Via Benzinga Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET May 09, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022 May 02, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 March 29, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV) February 17, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial February 16, 2022 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a... Via Benzinga Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 February 16, 2022 From Enanta Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.